Core Viewpoint - A shareholder has filed a securities class action lawsuit against RxSight, Inc. for allegedly overstating product demand and failing to disclose sales declines due to adoption challenges and structural issues [1][2]. Group 1 - The lawsuit represents investors who purchased or acquired RxSight's securities between November 7, 2024, and July 8, 2025 [1]. - Defendants are accused of not disclosing significant challenges that affected the company's sales performance [2]. - The deadline to file as a lead plaintiff in the class action is September 22, 2025 [3]. Group 2 - Bernstein Liebhard LLP has a history of recovering over $3.5 billion for clients and has represented large public and private pension funds [4]. - The firm has been recognized multiple times for its success in litigating class actions, being named to The National Law Journal's "Plaintiffs' Hot List" and listed in The Legal 500 [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of PepGen Inc. regarding a class action lawsuit due to alleged misleading statements related to the company's lead product candidate, PGN-EDO51 [1][3]. Summary by Relevant Sections Allegations - The complaint alleges that during the class period from March 7, 2024, to March 3, 2025, PepGen's management made materially false and misleading statements about PGN-EDO51, claiming it was more effective and safe than it actually was [3]. - It is claimed that the phase two CONNECT2 study was dangerous or deficient for FDA approval, leading to the likelihood of halting the study and overstating PGN-EDO51's clinical, regulatory, and commercial prospects [3]. Class Action Details - Shareholders who purchased shares during the specified class period are encouraged to register for the class action, with a deadline of August 8, 2025, to seek lead plaintiff status [4]. - Participants will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle, with no cost or obligation to participate [4]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit, fraud, and illegal business practices [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements that inflated stock prices [5].

Core Viewpoint - A shareholder has filed a securities class action lawsuit against Capricor Therapeutics, Inc. for alleged misrepresentations regarding the safety and efficacy data of its lead drug candidate, deramiocel, during a specific time frame [1][2]. Group 1: Lawsuit Details - The lawsuit represents investors who purchased Capricor's securities between October 9, 2024, and July 10, 2025 [1]. - The allegations focus on misrepresentations related to the four-year safety and efficacy data from the Phase 2 HOPE-2 trial of deramiocel, aimed at treating cardiomyopathy associated with Duchenne muscular dystrophy [2]. Group 2: Legal Process - Investors wishing to serve as lead plaintiff must file necessary documents by September 15, 2025, with the role involving representation of other class members in the litigation [3]. - Participation as a class member does not require serving as lead plaintiff, and all legal representation is on a contingency fee basis, meaning shareholders incur no fees or expenses [3]. Group 3: Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has represented both individual investors and large public and private pension funds [4]. - The firm has been recognized for its success in litigating class actions, being named to The National Law Journal's "Plaintiffs' Hot List" thirteen times and listed in The Legal 500 for sixteen consecutive years [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Organon & Co. securities during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The class period for the Organon securities lawsuit is from October 31, 2024, to April 30, 2025, inclusive [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the court to serve as lead plaintiff by July 22, 2025 [2]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time [3]. - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013 [3]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for clients [3]. Group 3: Case Allegations - The lawsuit alleges that Organon's defendants made misleading statements while concealing material adverse facts about the company's capital allocation priorities [4]. - Specifically, the lawsuit highlights that the defendants concealed the importance of Organon's debt reduction strategy following its acquisition of Dermavant, which led to a 70% decrease in the regular quarterly dividend [4]. - The lawsuit claims that investors suffered damages once the true details about the company's financial priorities were revealed [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Hims & Hers Health, Inc. due to allegations of securities law violations related to misleading statements and the promotion of unsafe products [3][5]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses exceeding $50,000 in Hims between April 29, 2025, and June 22, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Hims, with a deadline of August 25, 2025, for investors to seek the role of lead plaintiff [3][7]. - The complaint alleges that Hims engaged in deceptive practices by promoting illegitimate versions of Wegovy®, which jeopardized patient safety and misled investors about the company's operations and prospects [5]. Group 2: Partnership Termination and Stock Impact - Novo Nordisk announced the termination of its partnership with Hims on June 23, 2025, citing Hims' failure to comply with legal standards and the promotion of unsafe compounded drugs [6]. - Following the announcement, Hims' stock price dropped by $22.24, or 34.6%, closing at $41.98 per share, resulting in significant losses for investors [6]. Group 3: Call for Information - Faruqi & Faruqi is also seeking information from whistleblowers, former employees, and shareholders regarding Hims' conduct [8].

Core Viewpoint - A class action lawsuit has been filed against Petco Health and Wellness Company, Inc. for misleading statements made during the Class Period from January 14, 2021, to June 5, 2025, potentially affecting investors' financial interests [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Petco's pandemic-related growth was unsustainable and that the company's business model, which focuses on premium pet food, was overstated [5]. - Defendants allegedly failed to disclose the true scope of issues affecting Petco's business, including the necessary changes to address these issues and the negative impacts on comparable sales [5]. - The lawsuit asserts that public statements made by the defendants were materially false and misleading, leading to investor damages when the truth was revealed [5]. Group 2: Investor Participation - Investors who purchased Petco securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, investors can submit a form or contact the Rosen Law Firm for more information [3][6]. - A lead plaintiff is needed to represent the class, and interested parties must move the Court by August 29, 2025 [1][3]. Group 3: Rosen Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [4]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions of dollars for investors [4]. - Founding partner Laurence Rosen has been recognized as a leading figure in the plaintiffs' bar, further establishing the firm's credibility [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against 3D Systems Corporation due to alleged violations of federal securities laws, encouraging affected investors to come forward before the August 12, 2025 deadline for lead plaintiff applications in a federal securities class action [3][5]. Financial Performance - 3D Systems reported Q4 2024 non-GAAP earnings-per-share of -$0.19, missing consensus estimates by $0.08, with sales revenue of $111 million, reflecting a year-over-year decline of 3.4% and missing estimates by $4.17 million [6]. - For the full year 2024, the company reported sales of $440.1 million, a decrease of 10% compared to the previous year, attributed to lower hardware systems sales due to macroeconomic factors [6]. - In Q1 2025, 3D Systems reported revenue of $94.5 million, down 8% year-over-year, and a net loss of $37 million, or $0.28 per share, more than doubling the loss from Q1 2024 [8]. Stock Price Reaction - Following the Q4 2024 results announcement, 3D Systems' stock price fell by $0.57, or 20.96%, closing at $2.15 per share [7]. - After the Q1 2025 results were released, the stock price dropped by $0.68, or 26.6%, closing at $1.87 per share [9]. Allegations and Legal Context - The complaint against 3D Systems alleges that the company and its executives made false and misleading statements regarding customer spending and the impact on the company's business, as well as the revenue from its Regenerative Medicine Program [5]. - The firm is encouraging anyone with information regarding 3D Systems' conduct to come forward, including whistleblowers and former employees [11].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against 3D Systems Corporation due to alleged violations of federal securities laws, encouraging affected investors to come forward before the August 12, 2025 deadline for lead plaintiff applications in a federal securities class action [2][4]. Financial Performance - 3D Systems reported Q4 2024 non-GAAP earnings-per-share of -$0.19, missing consensus estimates by $0.08, with sales revenue of $111 million, reflecting a 3.4% year-over-year decline [5]. - For the full year 2024, the company reported sales of $440.1 million, a decrease of 10% compared to the previous year, attributed to lower hardware systems sales due to macroeconomic factors [5]. - In Q1 2025, 3D Systems reported revenue of $94.5 million, down 8% year-over-year, and a net loss of $37 million, or $0.28 per share, more than doubling the loss from Q1 2024 [6]. Stock Price Reaction - Following the Q4 2024 results announcement, 3D Systems' stock price fell by $0.57, or 20.96%, closing at $2.15 per share [5]. - After the Q1 2025 results were released, the stock price dropped by $0.68, or 26.6%, to close at $1.87 per share [7]. Allegations and Legal Context - The complaint against 3D Systems alleges that the company and its executives made false or misleading statements regarding the impact of weakened customer spending and the revenue from its Regenerative Medicine Program [4]. - The firm is encouraging anyone with information regarding 3D Systems' conduct to contact them, including whistleblowers and former employees [8].

Core Viewpoint - A class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. for allegedly providing misleading information regarding the safety and clinical trial protocol of its product RP-A501, leading to inflated stock prices and subsequent investor losses [1][5]. Group 1: Lawsuit Details - The class action lawsuit pertains to securities purchased between February 27, 2025, and May 26, 2025 [1]. - The lawsuit claims that Rocket Pharmaceuticals made positive statements while concealing serious adverse events, including participant deaths, related to RP-A501 [5]. - The company allegedly amended the trial protocol without informing shareholders, which contributed to the misleading nature of the information provided [5]. Group 2: Investor Information - Investors who purchased Rocket Pharmaceuticals securities during the class period may be entitled to compensation without upfront costs through a contingency fee arrangement [2]. - Interested investors can join the class action by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must be appointed by August 11, 2025, to represent the class in the lawsuit [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [4]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in handling such cases [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Red Cat Holdings, Inc. due to allegations of misleading statements regarding the company's production capacity and contract values, which have led to significant investor losses [2][4]. Group 1: Company Overview - Red Cat Holdings, Inc. (NASDAQ: RCAT) is involved in the production of small, portable drones for military applications, specifically under the U.S. Army's Short Range Reconnaissance Program [5]. - The company has faced scrutiny for overstating the production capacity of its Salt Lake City facility and the overall value of its contracts, particularly the SRR Contract [4][6]. Group 2: Financial Performance and Stock Impact - Following disclosures about the actual production capacity of the Salt Lake City facility being only 100 drones per month, Red Cat's stock price fell by 8.93% to close at $1.02 per share on July 28, 2023 [8]. - In the first quarter of fiscal year 2025, Red Cat reported losses per share of $0.17, missing consensus estimates by $0.09, and revenue of $2.8 million, missing estimates by $1.07 million [9]. - After a report from Kerrisdale Capital alleged that the SRR Contract was worth only $20 million to $25 million, Red Cat's stock price dropped by 21.54% to close at $8.56 per share on January 17, 2025 [12][13]. Group 3: Legal Proceedings - A federal securities class action has been filed against Red Cat, with a deadline of July 21, 2025, for investors to seek the role of lead plaintiff [2]. - The complaint alleges that Red Cat and its executives made materially false and misleading statements regarding the company's business and operations throughout the class period [4][6].